Morbidelli L, Maggi C A, Ziche M
Department of Preclinical and Clinical Pharmacology, Mario Aiazzi Mancini, University of Florence, Italy.
Neuropeptides. 1993 Jun;24(6):335-41. doi: 10.1016/0143-4179(93)90004-t.
The effect of synthetic selective tachykinin receptor antagonists was studied on the growth of cultured human skin fibroblasts (HF). Selective antagonists for the NK1 receptor ([D-Pro4, D-Trp7,9,Phe11]-SP(4-11), GR71251 and L 668,169) and the NK2 receptor (L 659,877) were tested against Substance P (SP), against the selective NK1 receptor agonist [beta-Ala4,Sar9, Met(O2)11]-SP(4-11) and against basic Fibroblast Growth Factor (bFGF). All the selective NK1 receptor antagonists, tested at the concentration of 10(-5)M, induced a significant displacement to the right of the dose-response curves induced by SP and by the selective NK1 receptor agonist. The selective NK2 receptor antagonist did not modify the proliferative response to the tachykinins used. The growth promoting effect of bFGF was not modified by any of the tachykinin antagonists tested. These results indicate that the newly developed receptor-selective tachykinin antagonists appear to be a useful tool to assess the biological effects of tachykinin in vitro on cultured isolated cells.
研究了合成的选择性速激肽受体拮抗剂对培养的人皮肤成纤维细胞(HF)生长的影响。针对神经激肽1(NK1)受体的选择性拮抗剂([D-脯氨酸4,D-色氨酸7,9,苯丙氨酸11]-P物质(4-11)、GR71251和L 668,169)以及针对神经激肽2(NK2)受体的拮抗剂(L 659,877),分别针对P物质(SP)、选择性NK1受体激动剂[β-丙氨酸4,肌氨酸9,甲硫氨酸(氧代)11]-P物质(4-11)以及碱性成纤维细胞生长因子(bFGF)进行了测试。所有在10^(-5)M浓度下测试的选择性NK1受体拮抗剂,均使由SP和选择性NK1受体激动剂诱导的剂量反应曲线显著右移。选择性NK2受体拮抗剂并未改变对所用速激肽的增殖反应。所测试的任何一种速激肽拮抗剂均未改变bFGF的促生长作用。这些结果表明,新开发的受体选择性速激肽拮抗剂似乎是评估速激肽在体外对培养的分离细胞生物学效应的有用工具。